113 related articles for article (PubMed ID: 19620934)
1. Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004.
Isa S; Kawaguchi T; Teramukai S; Minato K; Ohsaki Y; Shibata K; Yonei T; Hayashibara K; Fukushima M; Kawahara M; Furuse K; Mack PC
J Thorac Oncol; 2009 Sep; 4(9):1104-10. PubMed ID: 19620934
[TBL] [Abstract][Full Text] [Related]
2. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003.
Mack PC; Redman MW; Chansky K; Williamson SK; Farneth NC; Lara PN; Franklin WA; Le QT; Crowley JJ; Gandara DR;
J Clin Oncol; 2008 Oct; 26(29):4771-6. PubMed ID: 18779603
[TBL] [Abstract][Full Text] [Related]
3. Serum level of osteopontin as a prognostic factor in patients who underwent surgical resection for non-small-cell lung cancer.
Takenaka M; Hanagiri T; Shinohara S; Yasuda M; Chikaishi Y; Oka S; Shimokawa H; Nagata Y; Nakagawa M; Uramoto H; So T; Yamada S; Tanaka F
Clin Lung Cancer; 2013 May; 14(3):288-94. PubMed ID: 23122494
[TBL] [Abstract][Full Text] [Related]
4. Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer.
Ostheimer C; Bache M; Güttler A; Reese T; Vordermark D
BMC Cancer; 2014 Nov; 14():858. PubMed ID: 25416631
[TBL] [Abstract][Full Text] [Related]
5. Osteopontin expression is associated with platinum-based chemotherapy response and prognosis of patients with advanced non small cell lung cancer.
Zhang T; Zhang DM; Zhao D; Hou XM; Yang TN
J BUON; 2014; 19(3):742-8. PubMed ID: 25261661
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24.
Bar J; Ding K; Zhao H; Han L; Laurie SA; Seymour L; Addison CL; Shepherd FA; Goss GD; Dimitroulakos J; Bradbury PA
Clin Lung Cancer; 2015 Nov; 16(6):e189-201. PubMed ID: 26081815
[TBL] [Abstract][Full Text] [Related]
7. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer.
Joensuu H; Anttonen A; Eriksson M; Mäkitaro R; Alfthan H; Kinnula V; Leppä S
Cancer Res; 2002 Sep; 62(18):5210-7. PubMed ID: 12234986
[TBL] [Abstract][Full Text] [Related]
8. Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxel.
Di Maio M; Krzakowski M; Fougeray R; Kowalski DM; Gridelli C
Lung Cancer; 2012 Jul; 77(1):116-20. PubMed ID: 22361218
[TBL] [Abstract][Full Text] [Related]
9. Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.
Rouanne M; Adam J; Goubar A; Robin A; Ohana C; Louvet E; Cormier J; Mercier O; Dorfmüller P; Fattal S; de Montpreville VT; Lebret T; Dartevelle P; Fadel E; Besse B; Olaussen KA; Auclair C; Soria JC
BMC Cancer; 2016 Jul; 16():483. PubMed ID: 27422280
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of serum osteopontin levels in small cell lung cancer.
Xu C; Yuan Q; Wang W; Chi C; Zhang Q; Li L; Yang R; Wang Y
BMC Pulm Med; 2020 Sep; 20(1):235. PubMed ID: 32873264
[TBL] [Abstract][Full Text] [Related]
11. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients.
Brattström D; Bergqvist M; Larsson A; Holmertz J; Hesselius P; Rosenberg L; Brodin O; Wagenius G
Anticancer Res; 1998; 18(2A):1123-7. PubMed ID: 9615776
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.
Paz-Ares L; Bálint B; de Boer RH; van Meerbeeck JP; Wierzbicki R; De Souza P; Galimi F; Haddad V; Sabin T; Hei YJ; Pan Y; Cottrell S; Hsu CP; RamLau R
J Thorac Oncol; 2013 Mar; 8(3):329-37. PubMed ID: 23370314
[TBL] [Abstract][Full Text] [Related]
13. Blood serum proteins as biomarkers for prediction of survival, locoregional control and distant metastasis rate in radiotherapy and radio-chemotherapy for non-small cell lung cancer.
Suwinski R; Giglok M; Galwas-Kliber K; Idasiak A; Jochymek B; Deja R; Maslyk B; Mrochem-Kwarciak J; Butkiewicz D
BMC Cancer; 2019 May; 19(1):427. PubMed ID: 31068179
[TBL] [Abstract][Full Text] [Related]
14. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
Socinski MA; Bondarenko I; Karaseva NA; Makhson AM; Vynnychenko I; Okamoto I; Hon JK; Hirsh V; Bhar P; Zhang H; Iglesias JL; Renschler MF
J Clin Oncol; 2012 Jun; 30(17):2055-62. PubMed ID: 22547591
[TBL] [Abstract][Full Text] [Related]
15. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.
Goss GD; Arnold A; Shepherd FA; Dediu M; Ciuleanu TE; Fenton D; Zukin M; Walde D; Laberge F; Vincent MD; Ellis PM; Laurie SA; Ding K; Frymire E; Gauthier I; Leighl NB; Ho C; Noble J; Lee CW; Seymour L
J Clin Oncol; 2010 Jan; 28(1):49-55. PubMed ID: 19917841
[TBL] [Abstract][Full Text] [Related]
16. Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.
Young RJ; Tin AW; Brown NJ; Jitlal M; Lee SM; Woll PJ
Br J Cancer; 2012 Mar; 106(6):1153-9. PubMed ID: 22353811
[TBL] [Abstract][Full Text] [Related]
17. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
Ramlau R; Gorbunova V; Ciuleanu TE; Novello S; Ozguroglu M; Goksel T; Baldotto C; Bennouna J; Shepherd FA; Le-Guennec S; Rey A; Miller V; Thatcher N; Scagliotti G
J Clin Oncol; 2012 Oct; 30(29):3640-7. PubMed ID: 22965962
[TBL] [Abstract][Full Text] [Related]
18. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
Lynch TJ; Patel T; Dreisbach L; McCleod M; Heim WJ; Hermann RC; Paschold E; Iannotti NO; Dakhil S; Gorton S; Pautret V; Weber MR; Woytowitz D
J Clin Oncol; 2010 Feb; 28(6):911-7. PubMed ID: 20100966
[TBL] [Abstract][Full Text] [Related]
20. Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21.
Addison CL; Ding K; Zhao H; Le Maître A; Goss GD; Seymour L; Tsao MS; Shepherd FA; Bradbury PA
J Clin Oncol; 2010 Dec; 28(36):5247-56. PubMed ID: 21079146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
